期刊文献+

基于脱酰基酶转化阿尼芬净前体echinocandin B条件的研究

Study on the conditions of converting the anidulafungin precursor echinocandin B(ECB) with deacylase reaction
下载PDF
导出
摘要 脱酰基酶可以将echinocandin B(ECB)脱去酰基侧链得到ECB母核,用于化学合成抗真菌药阿尼芬净。本研究考察了以二甲基亚砜(DMSO)助溶剂的转化体系脱酰基酶对ECB转化的各因素,建立了转化工艺(磷酸缓冲浓度:0.02mol/L,pH7.0,KCl浓度:0.68mol/L,DMSO浓度:15%,ECB浓度:450mg/L,加酶量:10%,转化温度:40℃)。为了提高转化效率,探索了新的转化体系即以β-环糊精助溶剂的转化体系,其优势为:当ECB与β-环糊精的浓度比为1:6时,ECB可在体系中完全溶解,底物浓度可以达到2g/L。 The deacylase can take the acyl side chain off echinocandin B(ECB) and get the ECB's mother scaffold, which was used for the chemical synthesis of antifungal drug anidulafungin. This study investigated the factors of converting ECB in the DMSO system and established the conversion process (phosphate buffer concentration: 0.02mol/L, pH: 7.0, KCl concentration: 0.68mol/L, DMSO concentration: 15%, the ECB concentration: 450mg/L, enzyme amount: 10%, transformation temperature: 40℃). In order to improve the conversion efficiency, a new conversion system was explored, in which the cosolvent was β-cyclodextrin. The advantage is: when the ECB with β-cyclodextrin concentration ratio was 1:6, the ECB could be completely dissolved in the system and the substrate concentration can reach 2g/L.
作者 朱进伟 滕云 张敏 高祥 郑玲辉 Zhu Jin-wei;Teng Yun;Zhang Min;Gao Xiang;Zheng Ling-hui(Hisun Pharmaceutical(Hang Zhou)Co.Ltd,Hangzhou 311404;Zhejiang Hisun Pharmaceutical Co.,Ltd.,Taizhou 318000;Zhejiang Anti-fungal Drug Key Laboratory,Taizhou 318000)
出处 《中国抗生素杂志》 CAS CSCD 2018年第11期1376-1383,共8页 Chinese Journal of Antibiotics
关键词 ECHINOCANDIN B 转化 二甲基亚砜 Β-环糊精 Echinocandin B (ECB) Conversion Dimethylsulfoxide(DMSO) β-cyclodextrin
  • 相关文献

参考文献1

二级参考文献9

  • 1Debono M,Gordee R S.Antibiotics that inhibit fungal cell wall development[J].Annu Rev Microbiol,1994,48(12):471-497. 被引量:1
  • 2Murdoch D,Ptosker G L.Anidulafungin[J].Drug,2004,64(19):2249-2 258. 被引量:1
  • 3Espinel-Ingroff A.Invitroantifungal activities of anidulafungin and micafungin,licensed agents and the investigational triazole pesaconazole as determined by NCCLS methods for 12 052 fungal isolates:review of the Iiterature[J].Rev Iberoam Mico,2003,20(4):121-136. 被引量:1
  • 4Petraitiene R,Petraitis V,Groll AH,et al.Antifungal activity of LY303366,a novel echinocandin B,in experimental disseminated candidiasis in rabbits[J].Antimicrob Agents Chemother,1999,43(9):21478-2155. 被引量:1
  • 5Petraitis V,Petraitiene R,Groll AH,et al.Antifungal efficacy,safety,and single-dose pharmacokinetics of LY303366,a novel echinocandin B,in experimental pulmonary aspergillosis in persistently neutropenic rabbits[J].Antimicrob Agents Chemother,1998,42(11):2898-2 905. 被引量:1
  • 6Vazquez J A,Sobel J D.Anidulafungin:A Novel Echinocandin[J].Clin Infect Dis,2006,42(15):215-222. 被引量:1
  • 7Stogniew M,Pu F,Henkel T.Antifungal biotransformatation in humans is by degradation not metabolism[C] // Program and abstracts of 13rd European congress of clinical microbiology and infectious diseases,2003:1223. 被引量:1
  • 8Krause D,Simjee A E,Van Rensburg C,et al.A randomized,doubleblind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis[J].Clin Infect Dis,2004,39(6):770-775. 被引量:1
  • 9Krause D,Reinhardt J,Vazquez JA,et al.Phaes Ⅱ.randomized dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia[J].Antimicrob Agents Chemother,2004,48(6):2 012-2 014. 被引量:1

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部